Soleus Capital Management, L.P. Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001802630
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q4 2023 · 73 positions · Total reported value $901.25M · Top-10 concentration 45.1% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 72.6% · 27 new · 36 cut · 27 exited
Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q2 2026 → Q3 2026): -6.9% · vs SPY -9.0% · Prev Value $2.90B — last quarter positions weighted by this quarter price moves · ranking
Est. QTD Return (Q3 2026 → newest close): -1.4% · vs SPY -3.6% · Latest Value $2.81B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking
In its Q4 2023 13F filing, Soleus Capital Management, L.P. disclosed 73 equity positions with a combined reported value of $901.25M. The filing implies a moderately concentrated portfolio: its ten largest positions account for 45.1% of reported value. HoldingsHub classifies the profile as Small / Health Tilt / High Turnover.
The largest disclosed positions as of Q4 2023 were TEVA ($58.09M), UTHR ($54.85M), GSK ($47.38M). By sector, the heaviest allocations are Health Care 74.6%, Materials 1.1%. Versus the prior quarter, allocation shifted toward Health Care (+1.9pp) and away from Consumer Staples (-0.7pp), Other (-1.6pp).
Versus the prior quarter, Soleus Capital Management, L.P. opened 27 new positions, trimmed 36 and fully exited 27, a turnover rate of 72.6% of positions. The portfolio's overlap with the prior quarter was 53% of names.
The largest new positions opened in Q4 2023 were HCA ($27.47M), IDYA ($20.09M), PEN ($19.97M).
Of the 27 positions fully exited versus the prior quarter, the largest were XBI ($91.28M), PODD ($20.36M), EOLS ($18.99M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q4 2023)
- HCA HCA HEALTHCARE INC · $27.47M
- IDYA IDEAYA BIOSCIENCES INC · $20.09M
- PEN PENUMBRA INC · $19.97M
- TMDX TRANSMEDICS GROUP INC · $9.72M
- HARP HARPOON THERAPEUTICS INC · $9.33M
- RVMD REVOLUTION MEDICINES INC · $7.23M
- SILK SILK RD MED INC · $6.59M
- VRDN VIRIDIAN THERAPEUTICS INC · $3.01M
Fully Exited (vs previous quarter)
- XBI SPDR SERIES TRUST · prev qtr: $91.28M
- PODD INSULET CORP · prev qtr: $20.36M · history
- EOLS EVOLUS INC · prev qtr: $18.99M · history
- CRL CHARLES RIV LABS INTL INC · prev qtr: $18.83M
- AXSM AXSOME THERAPEUTICS INC. · prev qtr: $16.60M
- BHC BAUSCH HEALTH COS INC · prev qtr: $11.58M
- BNTX BIONTECH SE · prev qtr: $10.65M
- SLNO SOLENO THERAPEUTICS INC · prev qtr: $9.59M
Insider Transactions (Form 4)
Latest Soleus Capital Management, L.P. buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
| Transaction date | Activity | Security | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-06-11 | Conversion | Parabilis Medicines, Inc. | 527,070 | $9.48 | SEC filing |
| 2026-06-11 | Buy | Parabilis Medicines, Inc. | 125,000 | $20.00 | SEC filing |
| 2026-06-11 | Buy | Parabilis Medicines, Inc. | 375,000 | $20.00 | SEC filing |
Fund Profile
Soleus Capital Management, L.P. is an SEC-registered 13F filer based in Greenwich, CT, United States. As of Q3 2026 it reported 97 US equity positions with a combined value of $2.81B. HoldingsHub carries 13 quarters of its filings (Q3 2023–Q3 2026).
Firm Snapshot
- Headquarters: GREENWICH, CT, United States
- SEC registration: 801-118942 (status: Approved), registered 2020-06-25
- Regulatory AUM (Form ADV): $3.66B as of 2026-04-27
- Client mix (by RAUM): pension and profit-sharing plans 100%
- Manages 12 private funds, of which 1 hedge funds
Portfolio Structure
- 97 positions · $2.81B reported value (Q3 2026)
- Top 10 holdings = 53.0% of reported value
- Largest position: KRYS (KRYSTAL BIOTECH INC) at 13.5%
- Average position size: $29.00M
Sector Tilt
- Health Care 98.6%
- Information Technology 0.0%
- (classified holdings cover 99% of value)
Quarterly Activity
- Q3 2026: 27 new, 28 added, 36 reduced, 27 exited
- 6 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
5.56M | $58.09M | 6.45% | Reduce | |
| 2 |
|
249.45K | $54.85M | 6.09% | Reduce | |
| 3 |
|
1.28M | $47.38M | 5.26% | Add | |
| 4 |
|
746.62K | $46.42M | 5.15% | Add | |
| 5 |
|
7.23M | $38.16M | 4.23% | Add | |
| 6 |
|
8.96M | $36.66M | 4.07% | Reduce | |
| 7 |
|
73.71K | $33.74M | 3.74% | Add | |
| 8 |
|
2.18M | $31.76M | 3.52% | Add | |
| 9 |
|
643.21K | $30.53M | 3.39% | Add | |
| 10 |
|
4.33M | $28.56M | 3.17% | Add | |
| 11 |
|
771.70K | $28.05M | 3.11% | Reduce | |
| 12 |
|
101.50K | $27.47M | 3.05% | New | |
| 13 |
|
415.45K | $26.09M | 2.90% | Reduce | |
| 14 |
|
2.43M | $25.09M | 2.78% | Reduce | |
| 15 |
|
322.89K | $23.76M | 2.64% | Add | |
| 16 |
|
9.78M | $22.59M | 2.51% | Add | |
| 17 |
|
564.70K | $20.09M | 2.23% | New | |
| 18 |
|
79.40K | $19.97M | 2.22% | New | |
| 19 |
|
2.60M | $17.73M | 1.97% | Reduce | |
| 20 |
|
392.19K | $14.00M | 1.55% | Add | |
| 21 |
|
9.44M | $13.69M | 1.52% | Reduce | |
| 22 |
|
317.05K | $13.36M | 1.48% | Reduce | |
| 23 |
|
1.01M | $12.93M | 1.44% | Reduce | |
| 24 |
|
470.20K | $12.83M | 1.42% | Reduce | |
| 25 |
|
1.43M | $11.60M | 1.29% | Add | |
| 26 |
|
514.00K | $11.11M | 1.23% | Add | |
| 27 |
|
650.00K | $11.10M | 1.23% | Reduce | |
| 28 |
|
1.84M | $10.37M | 1.15% | Reduce | |
| 29 |
|
4.07M | $10.00M | 1.11% | Reduce | |
| 30 |
|
123.11K | $9.72M | 1.08% | New | |
| 31 |
|
820.64K | $9.33M | 1.03% | New | |
| 32 |
|
159.00K | $8.82M | 0.98% | Reduce | |
| 33 |
|
964.55K | $8.44M | 0.94% | Hold | |
| 34 |
|
847.14K | $8.39M | 0.93% | Reduce | |
| 35 |
|
302.58K | $8.32M | 0.92% | Reduce | |
| 36 |
|
436.20K | $8.12M | 0.90% | Add | |
| 37 |
|
9.87M | $7.79M | 0.86% | Add | |
| 38 |
|
4.80M | $7.78M | 0.86% | Add | |
| 39 |
|
252.00K | $7.23M | 0.80% | New | |
| 40 |
|
341.82K | $7.17M | 0.80% | Reduce | |
| 41 |
|
537.00K | $6.59M | 0.73% | New | |
| 42 |
|
217.40K | $6.10M | 0.68% | Reduce | |
| 43 |
|
167.10K | $5.18M | 0.57% | Reduce | |
| 44 |
|
40.00K | $4.96M | 0.55% | Reduce | |
| 45 |
|
59.50K | $4.70M | 0.52% | Reduce | |
| 46 |
|
555.00K | $4.51M | 0.50% | Reduce | |
| 47 |
|
301.00K | $4.49M | 0.50% | Reduce | |
| 48 |
|
1.38M | $3.87M | 0.43% | Hold | |
| 49 |
|
138.00K | $3.01M | 0.33% | New | |
| 50 |
|
130.00K | $2.79M | 0.31% | New | |
FAQ
What did Soleus Capital Management, L.P. buy in 2023-Q4?
In its 2023-Q4 13F filing, Soleus Capital Management, L.P. reported 73 equity positions worth $901.25M in aggregate; its largest disclosed positions were TEVA ($58.09M), UTHR ($54.85M), GSK ($47.38M).
How large is Soleus Capital Management, L.P.'s portfolio?
Soleus Capital Management, L.P. reported $901.25M of long equity holdings across 73 positions as of 2023-Q4. Top-10 holdings account for 45.1% of reported value.
What is Soleus Capital Management, L.P.'s investment style?
HoldingsHub classifies the portfolio as Small / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.